Article
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.
Science translational medicine - 3 Feb 2016
Arena Sabrina, Siravegna Giulia, Mussolin Benedetta, Kearns Jeffrey D, Wolf Beni B, Misale Sandra, Lazzari Luca, Bertotti Andrea, Trusolino Livio, Adjei Alex A, Montagut Clara, Di Nicolantonio Federica, Nering Rachel, Bardelli Alberto
Abstract excerpt
The anti-epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab are used to treat RAS wild-type colorectal cancers (CRCs), but their efficacy is limited by the emergence of acquired drug resistance. After EGFR blockade, about 20% of CRCs develop mutations in the EGFR extracellular domain (ECD) that impair antibody binding and are associated with clinical relapse. We hypothesized that EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.